Cargando…
Laparoscopic bowel resection combined with infliximab treatment (LaRIC) versus infliximab for terminal ileitis in Crohn’s disease: a randomised, controlled, open-label trial
INTRODUCTION: Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract with an increasing incidence and prevalence worldwide. The early use of anti-tumour necrosis factor agents, such as infliximab, in patients with an aggressive form of Crohn’s disease has become part of rou...
Autores principales: | Hao, Xiuxiu, Feng, Tienan, Yang, Yang, Shi, Yuan, Jing, Ran, Liu, Sailiang, Luo, Yang, Qiao, Yuqi, Zhong, Ming, Yu, Minhao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670938/ https://www.ncbi.nlm.nih.gov/pubmed/33199421 http://dx.doi.org/10.1136/bmjopen-2020-038429 |
Ejemplares similares
-
Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial)
por: Eshuis, Emma J, et al.
Publicado: (2008) -
Terminal ileitis is not always Crohn’s disease
por: Bojic, Daniela, et al.
Publicado: (2011) -
Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007) -
Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017) -
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)